Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease].
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C, Priori SG, Alonso García MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernández Burgos E, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Ardissino D, Avendano C, Blomström-Lundqvist C, Clément D, Drexler H, Ferrari R, Fox KA, Julian D, Kearney P, Klein W, Köber L, Mancia G, Nieminen M, Ruzillo W, Simoons M, Thygesen K, Tognoni G, Tritto I, Wallentin L; Task Force on ACE-inhibitors of the European Society of Cardiology; Comité de la ESC para la elaboracion de las Guías de Práctica Clínica. López-Sendón J, et al. Among authors: kober l. Rev Esp Cardiol. 2004 Dec;57(12):1213-32. doi: 10.1157/13069868. Rev Esp Cardiol. 2004. PMID: 15617645 Free article. Review. Spanish. No abstract available.
A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Køber L. Brendorp B, et al. Among authors: kober l. Drug Saf. 2002;25(12):847-65. doi: 10.2165/00002018-200225120-00003. Drug Saf. 2002. PMID: 12241126 Review.
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM; VALIANT Investigators. Velazquez EJ, et al. Among authors: kober l. Eur J Heart Fail. 2003 Aug;5(4):537-44. doi: 10.1016/s1388-9842(03)00112-0. Eur J Heart Fail. 2003. PMID: 12921816 Free article.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Pfeffer MA, et al. Among authors: kober l. N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10. N Engl J Med. 2003. PMID: 14610160 Free article. Clinical Trial.
[Golden time in acute myocardial infarction].
Torp-Pedersen CT, Køber L. Torp-Pedersen CT, et al. Among authors: kober l. Ugeskr Laeger. 2003 Oct 13;165(42):3999. Ugeskr Laeger. 2003. PMID: 14610831 Danish. No abstract available.
1,449 results